No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
RNAZ Transcode Therapeutics
- 0.820
- +0.113+15.98%
Close May 3 16:00 ET
- 0.785
- -0.035-4.23%
Post 19:57 ET
5.01MMarket Cap-7P/E (TTM)
1.050High0.695Low6.15MVolume0.750Open0.707Pre Close5.34MTurnover100.77%Turnover RatioLossP/E (Static)6.11MShares309.60052wk High3.05P/B5.01MFloat Cap0.42052wk Low--Dividend TTM6.11MShs Float5600.000Historical High--Div YieldTTM50.21%Amplitude0.420Historical Low0.867Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
TransCode Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/16/2024 536.81% HC Wainwright & Co. → $3 Reiterates Buy → Buy 04/03/2024 536.81% HC Wainwright & Co. →
TransCode Therapeutics: A Promising Oncology Investment With FDA-Backed Clinical Advancements
Express News | Transcode Therapeutics Announces FDA Clearance to Initiate Phase 1/2 Clinical Trial With Ttx-Mc138 in Patients With Advanced Solid Tumors
Promising Phase 0 Results and Upcoming Trial Boost Confidence in TransCode Therapeutics
Express News | HC Wainwright & Co. Reiterates Buy on TransCode Therapeutics, Maintains $3 Price Target
TransCode Therapeutics Reports FY Results
Comments
Therapeutics Company Secures FDA Clearance For Solid Tumor Clinical Trial
The Dawn of a New Era in Cancer Treatment: FDA Greenlights TransCode Therapeutics' Revolutionary Trial.
In a significant leap towards transforming cancer care, TransCode Therapeutics, Inc., a beacon of innovation in the oncology sphere, has received the much-anticipated nod from the U.S. Food and Drug Administration (FDA) to initiate a groundbreaking Phase 1/2 clinical trial. This trial is set to explore the potential of T...
In a significant leap towards transforming cancer care, TransCode Therapeutics, Inc., a beacon of innovation in the oncology sphere, has received the much-anticipated nod from the U.S. Food and Drug Administration (FDA) to initiate a groundbreaking Phase 1/2 clinical trial. This trial is set to explore the potential of T...
$Transcode Therapeutics(RNAZ.US$ Transcode Therapeutics Announces FDA Clearance to Initiate Phase 1/2 Clinical Trial With Ttx-Mc138 in Patients With Advanced Solid Tumors
6
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
STD0313 : you think it will try to cover that spike next week?